Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.

Published
02 June 2016
From
New York Times
A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.

Published
30 May 2016
From
Los Angeles Times
Rare but severe liver side-effects reported among South African patients starting efavirenz-based ART

Treatment with efavirenz has been associated with rare but severe liver complications among patients receiving antiretroviral therapy (ART) in South Africa. Writing in AIDS, investigators report three patterns

Published
27 May 2016
By
Michael Carter
In Option B+, side-effects and needing time to think are key reasons for not taking HIV medication

A qualitative study of women in Malawi who chose not to take HIV treatment as part of the country’s Option B+ programme, or who interrupted their treatment,

Published
19 May 2016
By
Roger Pebody
START study shows that people starting HIV treatment earlier have better quality of life

Rather than treatment side-effects having a negative impact on people’s quality of life when they start HIV treatment, data from the large randomised START study show a

Published
07 March 2016
By
Roger Pebody
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC, Emtriva), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched

Published
25 February 2016
By
Liz Highleyman
Gilead announces results from first study to evaluate switching to FTAF-based regimens from Truvada® (FTDF)-based regimens

Investigational F/TAF-based regimens demonstrate high rates of virologic suppression and improved renal and bone laboratory parameters compared to Truvada-based regimens.

Published
24 February 2016
From
Gilead press release
Bone density recovers quickly after stopping PrEP

Bone mineral density recovers within six months of stopping pre-exposure prophylaxis (PrEP) containing tenofovir, Bob Grant of the University of California, San Francisco reported on behalf of

Published
24 February 2016
By
Keith Alcorn
Tenofovir treatment raises the risk of broken bones

Treatment containing tenofovir is associated with a higher risk of bone fractures in people living with HIV, but a single infusion of zoledronic acid, a drug used in

Published
23 February 2016
By
Keith Alcorn
People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs

HIV-positive patients who are taking a large number of medications for the treatment of non-HIV-related conditions are at increased risk of stopping or changing their antiretroviral therapy (ART),

Published
27 January 2016
By
Michael Carter
← First12345...74Next →

Filter by country